NCT05338931 2022-05-26
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
AbClon
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT01003769 2020-06-16
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Terminated
NCT00891072 2013-01-10
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00275431 2011-06-29
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
Phase 2 Completed
NCT00440388 2010-08-27
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Ascenta Therapeutics
Phase 2 Completed
NCT00286780 2010-08-13
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Ascenta Therapeutics
Phase 2 Completed